FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128862391> ?p ?o ?g. }

• W2128862391 endingPage "535" @default.
• W2128862391 startingPage "527" @default.
• W2128862391 abstract "Summary Alpha-synuclein is the major protein in Lewy bodies, the hallmark pathological finding in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Although normally intracellular, it also can be secreted, so extracellular alpha-synuclein may contribute to neuronal injury. Serum antibodies to alpha-synuclein could exert protective effects by increasing alpha-synuclein's movement out of the brain and, if they cross the blood–brain barrier, by inhibiting its neurotoxic effects. The objective of this study was to measure antibody concentrations to alpha-synuclein monomer and soluble oligomers in three intravenous immunoglobulin (IVIG) preparations, Gamunex (Talecris Biotherapeutics), Gammagard (Baxter Healthcare) and Flebogamma (Grifols Biologicals). Antibodies were measured in native IVIG preparations and after antibody–antigen complex dissociation. IVIG's non-specific binding was subtracted from its total binding to alpha-synuclein to calculate specific anti-alpha-synuclein antibody concentrations. Specific antibodies to alpha-synuclein monomer and/or soluble oligomers were detected in all IVIG products. In native IVIG preparations, the highest anti-monomer concentrations were in Gammagard and the highest anti-oligomer concentrations were in Gamunex; the extent to which lot-to-lot variation may have contributed to these differences was not determined. Antibody–antigen complex dissociation had variable effects on these antibody levels. The IVIG preparations did not inhibit alpha-synuclein oligomer formation, although they changed the distribution and intensity of some oligomer bands on Western blots. The presence of antibodies to soluble alpha-synuclein conformations in IVIG preparations suggests that their effects should be studied in animal models of synucleinopathies, as a first step to determine their feasibility as a possible treatment for PD and other synucleinopathies." @default.
• W2128862391 created "2016-06-24" @default.
• W2128862391 creator A5034276701 @default.
• W2128862391 creator A5055301428 @default.
• W2128862391 creator A5064743664 @default.
• W2128862391 creator A5075719688 @default.
• W2128862391 date "2010-07-14" @default.
• W2128862391 modified "2023-10-06" @default.
• W2128862391 title "Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations" @default.
• W2128862391 cites W103502886 @default.
• W2128862391 cites W1579132652 @default.
• W2128862391 cites W1593340312 @default.
• W2128862391 cites W1963744520 @default.
• W2128862391 cites W1964222239 @default.
• W2128862391 cites W1966360490 @default.
• W2128862391 cites W1967549235 @default.
• W2128862391 cites W1977846417 @default.
• W2128862391 cites W1978266853 @default.
• W2128862391 cites W1979824159 @default.
• W2128862391 cites W1984031632 @default.
• W2128862391 cites W1989999317 @default.
• W2128862391 cites W1991675111 @default.
• W2128862391 cites W2004608981 @default.
• W2128862391 cites W2012961210 @default.
• W2128862391 cites W2013313629 @default.
• W2128862391 cites W2016823921 @default.
• W2128862391 cites W2020809906 @default.
• W2128862391 cites W2024347019 @default.
• W2128862391 cites W2041102231 @default.
• W2128862391 cites W2044636296 @default.
• W2128862391 cites W2045062740 @default.
• W2128862391 cites W2049737588 @default.
• W2128862391 cites W2050786534 @default.
• W2128862391 cites W2054546468 @default.
• W2128862391 cites W2059261643 @default.
• W2128862391 cites W2064275922 @default.
• W2128862391 cites W2091265794 @default.
• W2128862391 cites W2096576951 @default.
• W2128862391 cites W2108060249 @default.
• W2128862391 cites W2118325677 @default.
• W2128862391 cites W2123431154 @default.
• W2128862391 cites W2124220488 @default.
• W2128862391 cites W2127526725 @default.
• W2128862391 cites W2128631317 @default.
• W2128862391 cites W2145132429 @default.
• W2128862391 cites W2145864424 @default.
• W2128862391 cites W2147680452 @default.
• W2128862391 cites W2154737306 @default.
• W2128862391 cites W2163012098 @default.
• W2128862391 cites W2164627569 @default.
• W2128862391 cites W2166789153 @default.
• W2128862391 cites W2168126805 @default.
• W2128862391 doi "https://doi.org/10.1111/j.1365-2249.2010.04214.x" @default.
• W2128862391 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2962971" @default.
• W2128862391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20646004" @default.
• W2128862391 hasPublicationYear "2010" @default.
• W2128862391 type Work @default.
• W2128862391 sameAs 2128862391 @default.
• W2128862391 citedByCount "21" @default.
• W2128862391 countsByYear W21288623912012 @default.
• W2128862391 countsByYear W21288623912013 @default.
• W2128862391 countsByYear W21288623912014 @default.
• W2128862391 countsByYear W21288623912016 @default.
• W2128862391 countsByYear W21288623912017 @default.
• W2128862391 countsByYear W21288623912018 @default.
• W2128862391 countsByYear W21288623912020 @default.
• W2128862391 countsByYear W21288623912022 @default.
• W2128862391 crossrefType "journal-article" @default.
• W2128862391 hasAuthorship W2128862391A5034276701 @default.
• W2128862391 hasAuthorship W2128862391A5055301428 @default.
• W2128862391 hasAuthorship W2128862391A5064743664 @default.
• W2128862391 hasAuthorship W2128862391A5075719688 @default.
• W2128862391 hasBestOaLocation W21288623911 @default.
• W2128862391 hasConcept C142724271 @default.
• W2128862391 hasConcept C159654299 @default.
• W2128862391 hasConcept C178790620 @default.
• W2128862391 hasConcept C185592680 @default.
• W2128862391 hasConcept C203014093 @default.
• W2128862391 hasConcept C2777440831 @default.
• W2128862391 hasConcept C2778548049 @default.
• W2128862391 hasConcept C2779097696 @default.
• W2128862391 hasConcept C2779134260 @default.
• W2128862391 hasConcept C2779483572 @default.
• W2128862391 hasConcept C2779734285 @default.
• W2128862391 hasConcept C2780642029 @default.
• W2128862391 hasConcept C2781449126 @default.
• W2128862391 hasConcept C55493867 @default.
• W2128862391 hasConcept C71924100 @default.
• W2128862391 hasConceptScore W2128862391C142724271 @default.
• W2128862391 hasConceptScore W2128862391C159654299 @default.
• W2128862391 hasConceptScore W2128862391C178790620 @default.
• W2128862391 hasConceptScore W2128862391C185592680 @default.
• W2128862391 hasConceptScore W2128862391C203014093 @default.
• W2128862391 hasConceptScore W2128862391C2777440831 @default.
• W2128862391 hasConceptScore W2128862391C2778548049 @default.
• W2128862391 hasConceptScore W2128862391C2779097696 @default.
• W2128862391 hasConceptScore W2128862391C2779134260 @default.
• W2128862391 hasConceptScore W2128862391C2779483572 @default.

• next